跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 225 条关于
“ERBB”
全部
225
临床试验
147
药物
29
机构
1
资讯
48
去年
Puma Biotechnology Acquires Takeda's Aurora Kinase Inhibitor Alisertib for $7M Upfront
去年
Salubris Bio's JK07 Shows Promise in Phase 2 Heart Failure Trial
去年
Zenocutuzumab Achieves 30% Response Rate in NRG1 Fusion-Positive Solid Tumors, Receives FDA Approval
7天前
Iza-bren Hits Recommended Phase 3 Dose in EGFR-Mutated NSCLC, Advancing to IZABRIGHT-Lung01
2年前
One-Year Trastuzumab Improves Disease-Free Survival in ERBB2-Positive Breast Cancer
去年
High TIL Levels Could Enable Shorter Trastuzumab Treatment in Early ERBB2-Positive Breast Cancer
去年
HER2 Amplification Varies Significantly Across Cancers and Patient Subgroups, Study Finds
上个月
AAADV 2026 Workshop to Confront the Hardest Questions in Global Cancer Drug Development
去年
Dendritic Cell Immunotherapy Shows Promise in Early-Stage ERBB2-Positive Breast Cancer
4年前
Margetuximab Not Cost-Effective Compared to Trastuzumab for ERBB2-Positive Advanced Breast Cancer
第 1 页,共 5 页
上一页
下一页